RESEARCH COLLABORATION AND COMMERCIALIZATION AGREEMENTConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of October 20, 2006 (the “Effective Date”), is entered by and between CELLDEX THERAPEUTICS, INC., a New Jersey corporation, with a principal place of business at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey, NJ 08865, (“Celldex”) and the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with a registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland, and an office at 605 Third Avenue, 33rd Floor, New York, NY 10158 USA, (“Ludwig”).
Vaccine Adjuvant License and Collaboration AgreementConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota
This Agreement is made on the 30th day of May, 2008 (“Effective Date”) by and among 3M COMPANY (“3M”) and 3M INNOVATIVE PROPERTIES COMPANY (“3M IPC”), a wholly-owned subsidiary of 3M, both with a principal address as 3M Center, St. Paul, MN 55144 (collectively “3M”); and Celldex Therapeutics, with a principal address at 222 Cameron Drive Suite 400, Phillipsburg, NJ 08865 (“CELLDEX”).
ContractConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Southampton
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [*], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
